JP2012503203A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012503203A5 JP2012503203A5 JP2011528016A JP2011528016A JP2012503203A5 JP 2012503203 A5 JP2012503203 A5 JP 2012503203A5 JP 2011528016 A JP2011528016 A JP 2011528016A JP 2011528016 A JP2011528016 A JP 2011528016A JP 2012503203 A5 JP2012503203 A5 JP 2012503203A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- breast cancer
- antibody
- sample
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 40
- 206010006187 Breast cancer Diseases 0.000 claims description 29
- 208000026310 Breast neoplasm Diseases 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 17
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 6
- 239000012636 effector Substances 0.000 claims description 6
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 5
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 101150030083 PE38 gene Proteins 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 108010066676 Abrin Proteins 0.000 claims description 2
- 108030001720 Bontoxilysin Proteins 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 101150029707 ERBB2 gene Proteins 0.000 claims description 2
- 102100038595 Estrogen receptor Human genes 0.000 claims description 2
- 101150112800 PE35 gene Proteins 0.000 claims description 2
- -1 PE37 Proteins 0.000 claims description 2
- 108010039491 Ricin Proteins 0.000 claims description 2
- 230000005867 T cell response Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000036755 cellular response Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 102000003998 progesterone receptors Human genes 0.000 claims description 2
- 108090000468 progesterone receptors Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 20
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 101710112752 Cytotoxin Proteins 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000002619 cytotoxin Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 102000005705 Keratin-5 Human genes 0.000 description 1
- 108010070553 Keratin-5 Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9854808P | 2008-09-19 | 2008-09-19 | |
| US61/098,548 | 2008-09-19 | ||
| PCT/US2009/057578 WO2010033866A2 (en) | 2008-09-19 | 2009-09-18 | Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012503203A JP2012503203A (ja) | 2012-02-02 |
| JP2012503203A5 true JP2012503203A5 (enExample) | 2012-10-25 |
Family
ID=42040172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011528016A Pending JP2012503203A (ja) | 2008-09-19 | 2009-09-18 | 基底乳癌腫の診断および処置のためのｃｓｐｇ４に対するモノクローナル抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8486393B2 (enExample) |
| EP (1) | EP2338055A4 (enExample) |
| JP (1) | JP2012503203A (enExample) |
| AU (2) | AU2009293007B2 (enExample) |
| CA (1) | CA2737758C (enExample) |
| WO (1) | WO2010033866A2 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108129573B (zh) | 2007-09-21 | 2021-10-08 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| US8486393B2 (en) * | 2008-09-19 | 2013-07-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma |
| US8318162B2 (en) | 2009-07-16 | 2012-11-27 | Xoma Technology Ltd. | Antibodies to high molecular weight melanoma associated antigen |
| US20110243993A1 (en) * | 2010-03-29 | 2011-10-06 | Broo Kerstin S | Method for diagnosing and creating immunogenic tolerance in contact allergy and other epithelial immunotoxicological ailments |
| JP5451552B2 (ja) | 2010-08-09 | 2014-03-26 | オリンパス株式会社 | 顕微鏡システム、標本観察方法およびプログラム |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| ES2686692T3 (es) | 2013-09-24 | 2018-10-19 | Oncoinvent As | Anticuerpo monoclonal anti CD146 |
| WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| US20160032007A1 (en) * | 2014-04-28 | 2016-02-04 | Duke University | Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4) |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US11091547B2 (en) | 2014-11-12 | 2021-08-17 | Memorial Sloan Kettering Cancer Center | Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof |
| WO2016103205A1 (en) * | 2014-12-23 | 2016-06-30 | Universita' Degli Studi Di Parma | Pro-apoptotic anti-ng2/cspg4 antibodies and their uses for disease therapy |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016164429A1 (en) * | 2015-04-06 | 2016-10-13 | The General Hospital Corporation | Anti-cspg4 chimeric antigen receptors |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| CN108603200B (zh) | 2015-11-23 | 2022-08-19 | 诺华股份有限公司 | 优化的慢病毒转移载体及其用途 |
| EP3397756B1 (en) | 2015-12-30 | 2023-03-08 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| AU2018355427A1 (en) | 2017-10-25 | 2020-04-30 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| SG11202104136YA (en) | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| WO2021216916A1 (en) | 2020-04-22 | 2021-10-28 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins |
| EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AU2022267891A1 (en) | 2021-04-27 | 2023-11-09 | Novartis Ag | Viral vector production system |
| EP4444753A2 (en) * | 2021-12-07 | 2024-10-16 | Regents of the University of Minnesota | Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2023369684A1 (en) | 2022-10-26 | 2025-04-17 | Novartis Ag | Lentiviral formulations |
| EP4620979A1 (en) * | 2022-11-14 | 2025-09-24 | Cognano, Inc. | Antibody and method for producing antibody |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03501209A (ja) | 1988-05-17 | 1991-03-22 | フェロン、ソルダノ | 抗ヒト高分子量メラノーマ関連抗原に対する抗イディオタイプ抗体 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| EP1805214A2 (en) * | 2004-10-20 | 2007-07-11 | Friedrich-Alexander-Universität Erlangen-Nürnberg | T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use |
| AU2006226060A1 (en) | 2005-03-25 | 2006-09-28 | Glycart Biotechnology Ag | Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function |
| KR20090013752A (ko) * | 2006-03-16 | 2009-02-05 | 헬스 리서치 인코포레이티드 | 유방암 줄기세포 성장 및 전이 억제 |
| US8486393B2 (en) * | 2008-09-19 | 2013-07-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Monoclonal antibodies for CSPG4 for the diagnosis and treatment of basal breast carcinoma |
-
2009
- 2009-09-18 US US13/119,428 patent/US8486393B2/en not_active Expired - Fee Related
- 2009-09-18 CA CA2737758A patent/CA2737758C/en active Active
- 2009-09-18 EP EP09815308A patent/EP2338055A4/en not_active Withdrawn
- 2009-09-18 AU AU2009293007A patent/AU2009293007B2/en not_active Ceased
- 2009-09-18 JP JP2011528016A patent/JP2012503203A/ja active Pending
- 2009-09-18 WO PCT/US2009/057578 patent/WO2010033866A2/en not_active Ceased
-
2013
- 2013-06-18 US US13/921,133 patent/US9096661B2/en active Active
-
2015
- 2015-06-23 US US14/748,123 patent/US9801928B2/en active Active
- 2015-12-15 AU AU2015268743A patent/AU2015268743B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503203A5 (enExample) | ||
| US12453780B2 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use | |
| US10548987B2 (en) | Antibody-drug conjugates for targeting CD56-positive tumors | |
| US9409994B2 (en) | High-affinity monoclonal antibodies to glypican-3 and use thereof | |
| US9416190B2 (en) | Mesothelin antibodies and methods for eliciting potent antitumor activity | |
| US10052382B2 (en) | Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides | |
| US12122843B2 (en) | High affinity monoclonal antibodies targeting glypican-1 and methods of use | |
| JP2010510809A5 (enExample) | ||
| HK1255234A1 (zh) | 经半胱氨酸取代的免疫球蛋白 | |
| JP2013506428A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JP2016534735A5 (enExample) | ||
| WO2016022939A1 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
| WO2006039238A2 (en) | Irta2 antibodies and methods of use | |
| JP2014515600A5 (enExample) | ||
| CN115297890A (zh) | 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物 | |
| JPWO2022087243A5 (enExample) | ||
| CN120383678A (zh) | 识别磷脂酰肌醇蛋白聚糖3多个不同表位的抗体及其应用 | |
| US20250313626A1 (en) | Anti-cd200r1 antibodies | |
| US20110171216A1 (en) | Monoclonal antibodies specific for pancreatic neoplasia cells | |
| JPWO2023023354A5 (enExample) |